Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:7
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 36 条
  • [21] Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
    Trillsch, Fabian
    Mahner, Sven
    Ataseven, Beyhan
    Asher, Rebecca
    Aryal, Nanda
    Dubot, Coraline
    Clamp, Andrew
    Penson, Richard T.
    Oza, Amit
    Amit, Amnon
    Huzarski, Tomasz
    Casado, Antonio
    Scambia, Giovanni
    Friedlander, Michael
    Colombo, Nicoletta
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Denys, Hannelore
    Lowe, Elizabeth S.
    Lee, Chee K.
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2022, 165 (01) : 40 - 48
  • [22] Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
    Reiss, Kim A.
    Mick, Rosemarie
    O'Hara, Mark H.
    Teitelbaum, Ursina
    Karasic, Thomas B.
    Schneider, Charles
    Cowden, Stacy
    Southwell, Traci
    Romeo, Janae
    Izgur, Natallia
    Hannan, Zain M.
    Tondon, Rashmi
    Nathanson, Katherine
    Vonderheide, Robert H.
    Wattenberg, Max M.
    Beatty, Gregory
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2497 - +
  • [23] Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
    Delgado-Ortega, Laura
    Gines Rubio, Jordi
    Carmen de Espana, Maria del Carmen
    Carcedo, David
    Cordero Puentes, Luis
    Moya de Alarcon, Carlota
    FARMACIA HOSPITALARIA, 2018, 42 (03) : 95 - 102
  • [24] Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
    Wu, Lingying
    Zhu, Jianqing
    Yin, Rutie
    Wu, Xiaohua
    Lou, Ge
    Wang, Jing
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Zhou, Qi
    Wang, Yueling
    Chen, Youguo
    Lu, Weiguo
    Li, Wei
    Cheng, Ying
    Liu, Jihong
    Ma, Xin
    Zhang, Jing
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 175 - 181
  • [25] Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
    Cecere, Sabrina Chiara
    Giannone, Gaia
    Salutari, Vanda
    Arenare, Laura
    Lorusso, Domenica
    Ronzino, Graziana
    Lauria, Rossella
    Cormio, Gennaro
    Carella, Claudia
    Scollo, Paolo
    Ghizzoni, Viola
    Raspagliesi, Francesco
    Di Napoli, Marilena
    Mazzoni, Enrica
    Marchetti, Claudia
    Bergamini, Alice
    Orditura, Michele
    Valabrega, Giorgio
    Scambia, Giovanni
    Maltese, Giuseppa
    De Matteis, Elisabetta
    Cardalesi, Cinzia
    Loizzi, Vera
    Boccia, Serena
    Naglieri, Emanuele
    Scandurra, Giuseppa
    Pignata, Sandro
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 38 - 44
  • [26] Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
    Tan, David S. P.
    Chan, Jack Junjie
    Hettle, Robert
    Ghosh, Wrik
    Viswambaram, Amrita
    Yu, Cindy Chen
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (02) : 1 - 14
  • [27] Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer
    Bookman, Michael A.
    Tyczynski, Jerzy E.
    Espirito, Janet L.
    Wilson, Thomas W.
    Fernandes, Ancilla W.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 58 - 63
  • [28] Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
    Paik, E. Sun
    Lee, Yong Jae
    Lee, Jung-Yun
    Shin, Wonkyo
    Park, Sang-Yoon
    Kim, Se Ik
    Kim, Jae-Weon
    Choi, Chel Hun
    Kim, Byoung-Gie
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [29] Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Lou, Ge
    An, Ruifang
    Zhang, Guonan
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Zheng, Hong
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Hao, Min
    Huang, Yi
    Lin, Zhongqiu
    Wang, Dong
    Guo, Xiaoqing
    Yao, Shuzhong
    Wan, Xiaoyun
    Zhou, Huaijun
    Yao, Liangqing
    Yang, Xielan
    Cui, Heng
    Meng, Yuanguang
    Zhang, Songling
    Qu, Jing
    Zhang, Ben
    Zou, Jianjun
    Wu, Lingying
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (22) : 2436 - +
  • [30] Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
    Pan, Junjie
    Ren, Ning
    Ren, Lanqi
    Yang, YiBei
    Xu, Qiaoping
    SCIENTIFIC REPORTS, 2024, 14 (01):